ClinicalTrials.gg
CompletedNCT03574389Updated Nov 5, 2024Results posted

A Study Assessing 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Infants and Young Children

A Phase 3 interventional study of 13vPnC and Hib in Pneumococcal Infections and Pneumococcal Conjugate Vaccine, sponsored by Pfizer. Completed at 2 sites in China. Open to participants aged 42 Days to 5 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-05.

Sponsored by Pfizer · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
936
Allocation
Randomized
Ages
42 Days to 5 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections — none open to participants now, 1 under way, none of them phase 3. 13-valent pneumococcal vaccine · Pneumococcal Infections.

Enrollment
9th of 44
936 · median 328
Started
2018
with 5 others
Phase 3
19 of 44
none open now
Registered
32nd of 44
by date
Lead sponsor
16 of 44
Pfizer

Among the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections, this one is the 9th largest by enrollment, is one of 6 that started in 2018, is one of 19 in phase 3, and was the 32nd registered.

Pneumococcal Infections

298 studies on the registry are indexed under Pneumococcal Infections; 25 are open to participants now.

Browse Pneumococcal Infections studies →

Open to participants now

None of the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections is open now. The open studies under Pneumococcal Infections, anywhere →

About 13-valent pneumococcal vaccine

13-valent pneumococcal vaccine: first FDA approval 2010 (Prevnar 13). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.

This study: 42 Days to 5 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections as a file.
02

Study summary

The purpose of this study is to assess the safety and immunogenicity of 13-valent Pneumococcal conjugate vaccine in Chinese infant and young children.

03

Conditions studied

  • Pneumococcal Infections
  • Pneumococcal Conjugate Vaccine
04

Who can participate

Ages eligible
42 Days to 5 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Evidence of a personally signed and dated ICD indicating that the parent(s)/legal guardian has been informed of all pertinent aspects of the study.
  • Aged 6 weeks (42 days) to \<6 years at the time of consent.
  • Healthy infants and children as determined by medical history, physical examination, and judgment of the investigator.

Exclusion criteria

Exclusion Criteria:

  • Participation in other studies involving drug(s)/vaccine(s) since birth (Cohort 1 only) or in the 6 months prior to study entry (Cohorts 2, 3, and 4) and/or during study participation.
  • Other acute or chronic medical or psychiatric condition, including recent laboratory abnormality, that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
  • Vaccination with licensed or investigational pneumococcal vaccine.
  • Previous vaccination with licensed or investigational Hib vaccine.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
936 participants (actual)

Study arms

  • Experimental
    13-valent Pneumococcal Conjugate Vaccine (13vPnC)

    1. Participants in cohort 1 will receive each dose of 13vPnC in months 2, 4 and 6, and then a booster dose during months 12-15. 2. Participants in cohort 2 will receive first dose dose 13vPnC at the age of months 7(included) to months 12 (less than months 12), and the second dose will be given at least 28 days after first dose, and the third dose will be months 12 to 15 (and at least 56 days after the second dose). 3. Participants in cohort 3 will receive the first dose of 13vPnC during 1 (included) to 2 years (less than 2 years of age) of age, and the second dose will be given at least 56 days after first dose. 4. Participants in cohort 4 will receive only one dose at the age of 2 (included) to 6 (less than 6 years of age) years of age.

    Biological: 13vPnC

  • Active comparator
    Haemophilus influenzae type b (Hib)

    1. No participants in cohort 1 will receive Hib vaccine. 2. Participants in cohort 2 will receive the first dose of Hib vaccine at the age of months 7 (included) to 12 (less than 12 months), and the second dose will be given at least 28 days after the first dose, the third dose will following local practice or national recommendation at the discretion of the investigator. 3. Participants in cohorts 3 and 4 will receive the only one dose Hib vaccine at the age of 1 (included) to 6 (less than 6 years) years of age.

    Biological: Hib

Interventions

  • Biological13vPnC

    suspension in prefilled syringe for intramuscular injection, 0.5 mL, only one dose

  • BiologicalHib

    suspension in prefilled syringe for intramuscular injection, 0.5 mL, only one dose

06

What researchers measure

Primary outcomes

  1. The Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for Each of the Pneumococcal Serotypes Measured in Cohorts 2, 3 and 4 Compared to IgG GMCs Measured in Cohort 1

    Serotype-specific IgG concentrations to the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in all participants from the blood samples taken 1 month after the infant series in Cohort 1 and the last dose 13vPnC in Cohorts 2, 3, 4. GMC and corresponding 2-sided 95% confidence intervals (CI) were evaluated. Geometric means (GMs) were calculated using all participants with available data for the specified blood draw.

    Time frame: Cohort 1: 1 month after the 3rd dose of 13vPnC (infant series dose). Cohort 2, 3, 4: 1 month after the last dose of 13vPnC.

  2. Number of Participants With Local Reactions and Systemic Events Within 7 Days After Each Vaccination in Cohort 2

    Local reactions (redness, swelling, and tenderness) at the site of the investigational product injection were monitored daily for 7 days after each vaccination. Temperature were collected at bedtime daily for 7 days and at any time during the 7 days that fever is suspected. Fever is defined as temperature of greater than or equal to 38.0ºC (100.4ºF). Other systemic events (decreased appetite, drowsiness and irritability) were recorded for 7 days after each investigational product vaccination.

    Time frame: Within 7 Days After Each Vaccination

  3. Number of Participants With Local Reactions and Systemic Events Within 7 Days After Each Vaccination in Cohort 3

    Local reactions (redness, swelling, and tenderness) at the site of the investigational product injection were monitored daily for 7 days after each vaccination. Temperature were collected at bedtime daily for 7 days and at any time during the 7 days that fever is suspected. Fever is defined as temperature of greater than or equal to 38.0ºC (100.4ºF). Other systemic events (decreased appetite, drowsiness and irritability) were recorded for 7 days after each investigational product vaccination.

    Time frame: Within 7 Days After Each Vaccination

  4. Number of Participants With Local Reactions and Systemic Events Within 7 Days After Each Vaccination in Cohort 4

    Local reactions (redness, swelling, and tenderness) at the site of the investigational product injection were monitored daily for 7 days after each vaccination. Temperature were collected at bedtime daily for 7 days and at any time during the 7 days that fever is suspected. Fever is defined as temperature of greater than or equal to 38.0ºC (100.4ºF). Other systemic events (fatigue, headache, vomiting, diarrhea, muscle pain and joint pain) were recorded for 7 days after each investigational product vaccination.

    Time frame: Within 7 Days After Each Vaccination

  5. Number of Participants With Adverse Event (AE) From the Signing of the Informed Consent Document (ICD) to 1 Month After the Last Vaccination in Cohorts 2, 3, 4

    An AE was any untoward medical occurrence in a study participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage.

    Time frame: From the signing of ICD to 1 month after the last vaccination (13vPnC or Hib) in Cohort 2, 3 and 4.

  6. Number of Participants With Newly Diagnosed Chronic Medical Conditions (NDCMCs) From 1 Month to 6 Months After the Last Vaccination in Cohorts 2, 3, 4

    Number of participants with NDCMCs from 1 month after the last study vaccination (13vPnC or Hib vaccine) to 6 months after the last study vaccination in Cohorts 2, 3, and 4. An NDCMC was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects.

    Time frame: From 1 month to 6 months (5 months) after the last vaccination in Cohorts 2,3,4.

  7. Number of Participants With SAE From the Signing of the ICD to 6 Months After the Last Vaccination in Cohorts 2, 3, 4

    An SAE was any untoward medical occurrence at any dose that resulted in death, was life-threatening (immediate risk of death), required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect or considered to be an important medical event.

    Time frame: From the signing of ICD to 6 month after the last vaccination (13vPnC or Hib) in Cohorts 2, 3 and 4.

Secondary outcomes

  1. The Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for Each of the Pneumococcal Serotypes Measured in Cohorts 2, 3 and 4 Compared to IgG GMTs Measured in Cohort 1.

    Serotype-specific OPA titers to the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in a randomly selected subset of about 50 participants receiving 13vPnC from the blood samples taken 1 month after the infant series in Cohort 1 and the last 13vPnC vaccination in each of the 3 cohorts. GMT and corresponding 2-sided 95% CI were evaluated. GMs were calculated using all participants with available data for the specified blood draw.

    Time frame: Cohort 1: 1 month after the 3rd dose of 13vPnC. Cohort 2, 3, 4: 1 month after the last dose of 13vPnC.

  2. The Serotype-specific IgG GMCs for Each of the Pneumococcal Serotypes in Cohorts 2, 3, 4 Vaccinated With 13 vPnC Compared to Cohorts 2, 3 and 4 Vaccinated With Hib Vaccine.

    Serotype-specific IgG concentrations to the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in all participants from the blood samples taken before vaccination and 1 month after vaccination in each of the 3 cohorts. GMC and corresponding 2-sided 95% CI were evaluated. GMs were calculated using all participants with available data for the specified blood draw.

    Time frame: Cohort 2, 3, 4: Before Vaccination and 1 Month After the Last Dose

  3. The Serotype-specific OPA GMT for Each of the Pneumococcal Serotypes in Cohorts 2, 3, 4 Vaccinated With 13 vPnC Compared to Cohorts 2, 3 and 4 Vaccinated With Hib Vaccine.

    Serotype-specific OPA titers to the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in a randomly selected subset of approximately 50 participants receiving 13vPnC and approximately 25 participants receiving Hib vaccine from the blood samples taken before vaccination and 1 month after the last 13vPnC vaccination in each of the 3 cohorts.

    Time frame: Cohort 2, 3, 4: Before Vaccination and 1 Month After the Last Dose

  4. Percentage of Participants Achieving Pneumococcal Serotype-specific IgG Concentration ≥0.35 mcg/mL for 1 Month After the Last Vaccination in Cohorts 2,3,4 (13vPnC and Hib Vaccine) and 1 Month After the Infant Series in Cohort 1 (13vPnC).

    Serotype-specific IgG concentrations to the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in all participants from the blood samples taken 1 month after the infant series in Cohort 1 and the last dose of vaccination (13vPnC or Hib vaccine) in Cohorts 2, 3, 4.

    Time frame: Cohort 1: 1 month after the 3rd dose of 13vPnC. Cohorts 2, 3, 4: 1 month after the last dose of 13vPnC and Hib Vaccine.

  5. Percentage of Participants Achieving Serotype-specific Pneumococcal OPA Titer ≥ Lower Limit of Quantitation (LLOQ) for 1 Month After the Last Vaccination in Cohorts 2,3,4 (13vPnC and Hib Vaccine) and 1 Month After the Infant Series in Cohort 1 (13vPnC).

    Serotype-specific OPA titers to the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in a randomly selected subset of about 50 participants receiving 13vPnC from the blood samples taken 1 month after the infant series in Cohort 1 and the last vaccination (13vPnC or Hib vaccine) in each of the 3 cohorts.

    Time frame: Cohort 1: 1 month after the 3rd dose of 13vPnC. Cohorts 2, 3, 4: 1 month after the last dose of 13vPnC and Hib Vaccine.

  6. Number of Participants With AE From the Signing of the ICD to 1 Month After the Infant Series in Cohort 1

    An AE was any untoward medical occurrence in a study participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage.

    Time frame: From the signing of ICD to 1 month after the 3rd dose of 13vPnC in Cohort 1.

  7. Number of Participants With NDCMCs From 1 Month After Vaccination 3 to Vaccination 4 in Cohort 1

    Number of Participants With NDCMCs from 1 month after vaccination 3 to vaccination 4 in Cohort 1. An NDCMC was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects.

    Time frame: From 1 month after Vaccination 3 to Vaccination 4.

  8. Number of Participants With AE From Toddler Dose Until 1 Month After the Toddler Dose in Cohort 1

    Number of Participants With AEs from vaccination 4 to 1 month after vaccination 4 in Cohort 1. An AE was any untoward medical occurrence in a study participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage.

    Time frame: From Vaccination 4 to 1 month after Vaccination 4 in Cohort 1.

  9. Number of Participants With NDCMCs From 1 Month to 6 Months After the Toddler Dose in Cohort 1

    Number of Participants With NDCMCs from 1 month after vaccination 4 to 6 months after vaccination 4 in Cohort 1. An NDCMC was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects.

    Time frame: From 1 month to 6 months (5 months) after Vaccination 4 in Cohort 1.

  10. Number of Participants With SAEs From the Signing of the ICD to 6 Months After the Toddler Dose in Cohort 1

    Number of Participants With SAEs from the signing of the ICD to 6 months after vaccination 4. An SAE was any untoward medical occurrence at any dose that resulted in death, was life-threatening (immediate risk of death), required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect or considered to be an important medical event.

    Time frame: From the Signing of the ICD to 6 Months After the Vaccination 4.

  11. Serotype-specific IgG GMCs for Each of the Pneumococcal Serotypes in Cohort 1 at 12, 24, 36 and 48 Months After Last Vaccination in Cohort 1 (Infant Series)

    Serotype-specific IgG concentrations to the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in all participants from the blood samples taken after last vaccination in Cohort 1. GMC and corresponding 2-sided 95% CI were evaluated. GMs were calculated using all participants with available data for the specified blood draw.

    Time frame: Cohort 1 (infant series): 12, 24, 36 and 48 Months After Last Vaccination in Cohort 1

07

Results

Posted Apr 26, 2024

Participant flow

This study presents results following completion of all vaccinations, including data from 6-month follow-up after the last study vaccination. This study was conducted in China.

Vaccination Period
Participant flow — Vaccination Period
MilestoneCohort 1Cohort 2_13vPnCCohort 2_Hib VaccineCohort 3_13vPnCCohort 3_Hib VaccineCohort 4_13vPnCCohort 4_Hib Vaccine
Started1252361171658313868
Vaccination 11252361171658313868
Vaccination 2114219107146000
Vaccination 311121400000
Vaccination 492000000
Completed902141071468313868
Not completed35221019000
Withdrew: Noncompliance with investigational product3000000
Withdrew: Withdrawal by parent/guardian26211019000
Withdrew: Other6000000
Withdrew: Adverse event0100000
Follow-up Period
Participant flow — Follow-up Period
MilestoneCohort 1Cohort 2_13vPnCCohort 2_Hib VaccineCohort 3_13vPnCCohort 3_Hib VaccineCohort 4_13vPnCCohort 4_Hib Vaccine
Started902141071468313868
Completed89201981377613167
Not completed11399771
Withdrew: Withdrawal by parent/guardian11399771

Outcome measures

PrimaryThe Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for Each of the Pneumococcal Serotypes Measured in Cohorts 2, 3 and 4 Compared to IgG GMCs Measured in Cohort 1

Serotype-specific IgG concentrations to the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in all participants from the blood samples taken 1 month after the infant series in Cohort 1 and the last dose 13vPnC in Cohorts 2, 3, 4. GMC and corresponding 2-sided 95% confidence intervals (CI) were evaluated. Geometric means (GMs) were calculated using all participants with available data for the specified blood draw.

Time frame:
Cohort 1: 1 month after the 3rd dose of 13vPnC (infant series dose). Cohort 2, 3, 4: 1 month after the last dose of 13vPnC.
Reported as:
Geometric mean · mcg/mL
The Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for Each of the Pneumococcal Serotypes Measured in Cohorts 2, 3 and 4 Compared to IgG GMCs Measured in Cohort 1
mcg/mLCohort 1_Infant SeriesCohort 2_13vPnCCohort 3_13vPnCCohort 4_vPnC
Serotype 15.40 (4.43 to 6.58)3.75 (3.26 to 4.32)4.38 (3.75 to 5.11)4.40 (3.76 to 5.14)
Serotype 30.63 (0.54 to 0.75)1.19 (1.08 to 1.32)1.32 (1.16 to 1.51)1.12 (0.97 to 1.29)
Serotype 43.96 (3.24 to 4.84)2.97 (2.60 to 3.40)4.04 (3.48 to 4.68)4.47 (3.92 to 5.10)
Serotype 53.50 (2.91 to 4.19)3.07 (2.73 to 3.46)2.57 (2.26 to 2.92)2.92 (2.57 to 3.32)
Serotype 6A5.35 (4.44 to 6.44)3.12 (2.74 to 3.57)3.19 (2.69 to 3.78)3.39 (2.80 to 4.09)
Serotype 6B4.62 (3.76 to 5.69)2.20 (1.91 to 2.54)2.47 (2.06 to 2.96)2.96 (2.44 to 3.59)
Serotype 7F7.14 (6.00 to 8.50)5.73 (5.10 to 6.44)7.87 (6.90 to 8.96)7.08 (6.19 to 8.10)
Serotype 9V3.66 (2.99 to 4.50)2.24 (1.99 to 2.51)3.31 (2.90 to 3.77)3.68 (3.22 to 4.21)
Serotype 1415.09 (11.39 to 20.00)10.89 (9.59 to 12.35)9.79 (8.40 to 11.41)6.94 (5.53 to 8.70)
Serotype 18C4.94 (4.11 to 5.94)2.25 (1.98 to 2.57)3.88 (3.25 to 4.64)5.60 (4.74 to 6.62)
Serotype 19A3.44 (2.85 to 4.16)3.62 (3.30 to 3.97)5.55 (4.86 to 6.34)11.62 (9.75 to 13.86)
Serotype 19F4.95 (3.91 to 6.26)4.50 (3.98 to 5.09)5.04 (4.28 to 5.92)5.44 (4.46 to 6.64)
Serotype 23F4.36 (3.23 to 5.88)2.04 (1.76 to 2.37)2.26 (1.90 to 2.67)2.80 (2.33 to 3.36)
PrimaryNumber of Participants With Local Reactions and Systemic Events Within 7 Days After Each Vaccination in Cohort 2

Local reactions (redness, swelling, and tenderness) at the site of the investigational product injection were monitored daily for 7 days after each vaccination. Temperature were collected at bedtime daily for 7 days and at any time during the 7 days that fever is suspected. Fever is defined as temperature of greater than or equal to 38.0ºC (100.4ºF). Other systemic events (decreased appetite, drowsiness and irritability) were recorded for 7 days after each investigational product vaccination.

Time frame:
Within 7 Days After Each Vaccination
Reported as:
Count of participants · Participants
Number of Participants With Local Reactions and Systemic Events Within 7 Days After Each Vaccination in Cohort 2
ParticipantsCohort 2_13vPnC_Vaccination 1Cohort 2_Hib Vaccine_Vaccination 1Cohort 2_13vPnC_Vaccination 2Cohort 2_Hib Vaccine_Vaccination 2Cohort 2_13vPnC_Vaccination 3
Local Reactions661820144
Systemic Events2372351
PrimaryNumber of Participants With Local Reactions and Systemic Events Within 7 Days After Each Vaccination in Cohort 3

Local reactions (redness, swelling, and tenderness) at the site of the investigational product injection were monitored daily for 7 days after each vaccination. Temperature were collected at bedtime daily for 7 days and at any time during the 7 days that fever is suspected. Fever is defined as temperature of greater than or equal to 38.0ºC (100.4ºF). Other systemic events (decreased appetite, drowsiness and irritability) were recorded for 7 days after each investigational product vaccination.

Time frame:
Within 7 Days After Each Vaccination
Reported as:
Count of participants · Participants
Number of Participants With Local Reactions and Systemic Events Within 7 Days After Each Vaccination in Cohort 3
ParticipantsCohort 3_13vPnC _Vaccination 1Cohort 3_Hib Vaccine_Vaccination 1Cohort 3_13vPnC _Vaccination 2
Local Reactions45109
Systemic Events2674
PrimaryNumber of Participants With Local Reactions and Systemic Events Within 7 Days After Each Vaccination in Cohort 4

Local reactions (redness, swelling, and tenderness) at the site of the investigational product injection were monitored daily for 7 days after each vaccination. Temperature were collected at bedtime daily for 7 days and at any time during the 7 days that fever is suspected. Fever is defined as temperature of greater than or equal to 38.0ºC (100.4ºF). Other systemic events (fatigue, headache, vomiting, diarrhea, muscle pain and joint pain) were recorded for 7 days after each investigational product vaccination.

Time frame:
Within 7 Days After Each Vaccination
Reported as:
Count of participants · Participants
Number of Participants With Local Reactions and Systemic Events Within 7 Days After Each Vaccination in Cohort 4
ParticipantsCohort 4_13vPnC_Vaccination 1Cohort 4_Hib Vaccine_Vaccination 1
Local Reactions4821
Systemic Events1710
PrimaryNumber of Participants With Adverse Event (AE) From the Signing of the Informed Consent Document (ICD) to 1 Month After the Last Vaccination in Cohorts 2, 3, 4

An AE was any untoward medical occurrence in a study participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage.

Time frame:
From the signing of ICD to 1 month after the last vaccination (13vPnC or Hib) in Cohort 2, 3 and 4.
Reported as:
Count of participants · Participants
Number of Participants With Adverse Event (AE) From the Signing of the Informed Consent Document (ICD) to 1 Month After the Last Vaccination in Cohorts 2, 3, 4
ParticipantsCohort 2_13vPnCCohort 2_Hib VaccineCohort 3_13vPnCCohort 3_Hib VaccineCohort 4_13vPnCCohort 4_Hib Vaccine
Number of Participants With Adverse Event (AE) From the Signing of the Informed Consent Document (ICD) to 1 Month After the Last Vaccination in Cohorts 2, 3, 47629211111
PrimaryNumber of Participants With Newly Diagnosed Chronic Medical Conditions (NDCMCs) From 1 Month to 6 Months After the Last Vaccination in Cohorts 2, 3, 4

Number of participants with NDCMCs from 1 month after the last study vaccination (13vPnC or Hib vaccine) to 6 months after the last study vaccination in Cohorts 2, 3, and 4. An NDCMC was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects.

Time frame:
From 1 month to 6 months (5 months) after the last vaccination in Cohorts 2,3,4.
Reported as:
Count of participants · Participants
Number of Participants With Newly Diagnosed Chronic Medical Conditions (NDCMCs) From 1 Month to 6 Months After the Last Vaccination in Cohorts 2, 3, 4
ParticipantsCohort 2_13vPnCCohort 2_Hib VaccineCohort 3_13vPnCCohort 3_Hib VaccineCohort 4_13vPnCCohort 4_Hib Vaccine
Number of Participants With Newly Diagnosed Chronic Medical Conditions (NDCMCs) From 1 Month to 6 Months After the Last Vaccination in Cohorts 2, 3, 4000000
PrimaryNumber of Participants With SAE From the Signing of the ICD to 6 Months After the Last Vaccination in Cohorts 2, 3, 4

An SAE was any untoward medical occurrence at any dose that resulted in death, was life-threatening (immediate risk of death), required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect or considered to be an important medical event.

Time frame:
From the signing of ICD to 6 month after the last vaccination (13vPnC or Hib) in Cohorts 2, 3 and 4.
Reported as:
Count of participants · Participants
Number of Participants With SAE From the Signing of the ICD to 6 Months After the Last Vaccination in Cohorts 2, 3, 4
ParticipantsCohort 2_13vPnCCohort 2_Hib VaccineCohort 3_13vPnCCohort 3_Hib VaccineCohort 4_13vPnCCohort 4_Hib Vaccine
Number of Participants With SAE From the Signing of the ICD to 6 Months After the Last Vaccination in Cohorts 2, 3, 4512021
SecondaryThe Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for Each of the Pneumococcal Serotypes Measured in Cohorts 2, 3 and 4 Compared to IgG GMTs Measured in Cohort 1.

Serotype-specific OPA titers to the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in a randomly selected subset of about 50 participants receiving 13vPnC from the blood samples taken 1 month after the infant series in Cohort 1 and the last 13vPnC vaccination in each of the 3 cohorts. GMT and corresponding 2-sided 95% CI were evaluated. GMs were calculated using all participants with available data for the specified blood draw.

Time frame:
Cohort 1: 1 month after the 3rd dose of 13vPnC. Cohort 2, 3, 4: 1 month after the last dose of 13vPnC.
Reported as:
Geometric mean · GMT
The Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for Each of the Pneumococcal Serotypes Measured in Cohorts 2, 3 and 4 Compared to IgG GMTs Measured in Cohort 1.
GMTCohort 1_Infant SeriesCohort 2_13vPnCCohort 3_13vPnCCohort 4_13vPnC
Serotype 1201.7 (134.8 to 301.8)142.7 (103.4 to 196.9)93.3 (70.1 to 124.1)40.9 (31.3 to 53.4)
Serotype 3112.9 (82.5 to 154.4)249.0 (205.7 to 301.5)332.3 (273.3 to 404.1)244.8 (192.0 to 312.1)
Serotype 41857.8 (1264.8 to 2728.8)2172.2 (1740.7 to 2710.7)2682.8 (2210.4 to 3256.2)4236.3 (3489.6 to 5142.8)
Serotype 5645.9 (452.6 to 921.8)286.3 (214.5 to 382.0)164.5 (131.5 to 205.7)79.3 (57.7 to 109.0)
Serotype 6A5996.2 (4337.5 to 8289.3)6042.7 (4830.2 to 7559.6)7661.8 (6116.0 to 9598.4)5849.3 (4364.0 to 7840.2)
Serotype 6B2331.6 (1481.3 to 3670.0)2181.6 (1350.1 to 3525.2)4986.3 (3717.6 to 6687.9)3775.2 (2825.1 to 5044.9)
Serotype 7F10413.4 (7373.1 to 14707.3)10234.6 (8612.2 to 12162.8)14963.5 (12367.6 to 18104.4)17107.3 (13842.7 to 21141.8)
Serotype 9V5386.5 (3634.0 to 7984.3)4154.1 (3358.6 to 5138.0)7220.1 (5620.9 to 9274.2)10533.5 (7811.9 to 14203.4)
Serotype 142859.4 (1688.9 to 4899.3)4108.0 (3342.6 to 5048.8)6885.4 (5642.6 to 8402.0)7504.5 (5718.2 to 9848.9)
Serotype 18C2677.9 (2000.3 to 3585.0)1486.6 (1124.6 to 1965.2)1890.4 (1429.0 to 2500.6)2111.9 (1630.6 to 2735.2)
Serotype 19A1677.3 (1159.9 to 2425.5)2611.3 (2071.6 to 3291.6)3560.0 (2867.8 to 4419.1)3055.1 (2154.1 to 4333.1)
Serotype 19F744.4 (506.7 to 1093.6)1158.4 (937.0 to 1432.1)1854.0 (1520.3 to 2260.8)1629.7 (1292.9 to 2054.2)
Serotype 23F3833.2 (2216.2 to 6630.1)5640.0 (3590.5 to 8859.4)6693.6 (4464.2 to 10036.4)4234.7 (2916.1 to 6149.5)
SecondaryThe Serotype-specific IgG GMCs for Each of the Pneumococcal Serotypes in Cohorts 2, 3, 4 Vaccinated With 13 vPnC Compared to Cohorts 2, 3 and 4 Vaccinated With Hib Vaccine.

Serotype-specific IgG concentrations to the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in all participants from the blood samples taken before vaccination and 1 month after vaccination in each of the 3 cohorts. GMC and corresponding 2-sided 95% CI were evaluated. GMs were calculated using all participants with available data for the specified blood draw.

Time frame:
Cohort 2, 3, 4: Before Vaccination and 1 Month After the Last Dose
Reported as:
Geometric mean · mcg/mL
The Serotype-specific IgG GMCs for Each of the Pneumococcal Serotypes in Cohorts 2, 3, 4 Vaccinated With 13 vPnC Compared to Cohorts 2, 3 and 4 Vaccinated With Hib Vaccine.
mcg/mLCohort 2_13vPnCCohort 2_Hib VaccineCohort 3_13vPnCCohort 3_Hib VaccineCohort 4_13vPnCCohort 4_Hib Vaccine
Serotype 1 - Before Vaccination0.02 (0.01 to 0.02)0.02 (0.01 to 0.03)0.07 (0.05 to 0.09)0.07 (0.05 to 0.10)0.18 (0.14 to 0.22)0.21 (0.15 to 0.28)
Serotype 1 - 1 Month After the Last Dose3.75 (3.26 to 4.32)0.04 (0.03 to 0.06)4.38 (3.75 to 5.11)0.07 (0.04 to 0.11)4.40 (3.76 to 5.14)0.16 (0.12 to 0.23)
Serotype 3 - Before Vaccination0.03 (0.03 to 0.04)0.03 (0.02 to 0.04)0.07 (0.05 to 0.09)0.07 (0.05 to 0.09)0.14 (0.10 to 0.18)0.13 (0.08 to 0.22)
Serotype 3 - 1 Month After the Last Dose1.19 (1.08 to 1.32)0.04 (0.03 to 0.05)1.32 (1.16 to 1.51)0.09 (0.06 to 0.13)1.12 (0.97 to 1.29)0.12 (0.07 to 0.20)
Serotype 4 - Before Vaccination0.01 (0.01 to 0.01)0.01 (0.01 to 0.01)0.03 (0.02 to 0.04)0.04 (0.03 to 0.06)0.07 (0.05 to 0.10)0.07 (0.05 to 0.11)
Serotype 4 - 1 Month After the Last Dose2.97 (2.60 to 3.40)0.02 (0.01 to 0.02)4.04 (3.48 to 4.68)0.03 (0.02 to 0.05)4.47 (3.92 to 5.10)0.06 (0.04 to 0.08)
Serotype 5 - Before Vaccination0.38 (0.34 to 0.43)0.36 (0.31 to 0.42)0.69 (0.60 to 0.78)0.63 (0.54 to 0.74)1.04 (0.92 to 1.17)0.97 (0.83 to 1.13)
Serotype 5 - 1 Month After the Last Dose3.07 (2.73 to 3.46)0.51 (0.43 to 0.61)2.57 (2.26 to 2.92)0.74 (0.62 to 0.88)2.92 (2.57 to 3.32)0.89 (0.73 to 1.07)
Serotype 6A - Before Vaccination0.15 (0.13 to 0.18)0.16 (0.13 to 0.20)0.30 (0.26 to 0.35)0.36 (0.30 to 0.42)0.79 (0.68 to 0.93)0.79 (0.64 to 0.97)
Serotype 6A - 1 Month After the Last Dose3.12 (2.74 to 3.57)0.20 (0.15 to 0.26)3.19 (2.69 to 3.78)0.42 (0.34 to 0.51)3.39 (2.80 to 4.09)0.80 (0.65 to 0.98)
Serotype 6B - Before Vaccination0.15 (0.12 to 0.17)0.15 (0.11 to 0.19)0.30 (0.26 to 0.35)0.35 (0.30 to 0.41)0.80 (0.69 to 0.94)0.70 (0.58 to 0.84)
Serotype 6B - 1 Month After the Last Dose2.20 (1.91 to 2.54)0.21 (0.16 to 0.26)2.47 (2.06 to 2.96)0.38 (0.32 to 0.46)2.96 (2.44 to 3.59)0.62 (0.49 to 0.79)
Serotype 7F - Before Vaccination0.03 (0.03 to 0.04)0.03 (0.02 to 0.04)0.10 (0.08 to 0.12)0.11 (0.08 to 0.15)0.25 (0.21 to 0.31)0.25 (0.18 to 0.33)
Serotype 7F - 1 Month After the Last Dose5.73 (5.10 to 6.44)0.05 (0.03 to 0.07)7.87 (6.90 to 8.96)0.13 (0.09 to 0.20)7.08 (6.19 to 8.10)0.21 (0.16 to 0.29)
Serotype 9V - Before Vaccination0.13 (0.11 to 0.16)0.16 (0.12 to 0.22)0.25 (0.20 to 0.31)0.27 (0.23 to 0.33)0.55 (0.47 to 0.65)0.41 (0.31 to 0.55)
Serotype 9V - 1 Month After the Last Dose2.24 (1.99 to 2.51)0.20 (0.14 to 0.27)3.31 (2.90 to 3.77)0.34 (0.26 to 0.43)3.68 (3.22 to 4.21)0.45 (0.37 to 0.54)
Serotype 14 - Before Vaccination0.03 (0.02 to 0.04)0.02 (0.02 to 0.03)0.03 (0.03 to 0.05)0.05 (0.03 to 0.09)0.19 (0.12 to 0.29)0.20 (0.11 to 0.36)
Serotype 14 - 1 Month After the Last Dose10.89 (9.59 to 12.35)0.02 (0.02 to 0.03)9.79 (8.40 to 11.41)0.07 (0.04 to 0.11)6.94 (5.53 to 8.70)0.20 (0.11 to 0.36)
Serotype 18C - Before Vaccination0.01 (0.01 to 0.01)0.01 (0.01 to 0.02)0.04 (0.03 to 0.06)0.05 (0.04 to 0.08)0.20 (0.15 to 0.27)0.20 (0.12 to 0.29)
Serotype 18C - 1 Month After the Last Dose2.25 (1.98 to 2.57)0.02 (0.01 to 0.03)3.88 (3.25 to 4.64)0.07 (0.04 to 0.12)5.60 (4.74 to 6.62)0.18 (0.11 to 0.29)
Serotype 19A - Before Vaccination0.36 (0.31 to 0.41)0.38 (0.31 to 0.46)0.65 (0.55 to 0.76)0.69 (0.58 to 0.83)1.72 (1.46 to 2.02)1.44 (1.13 to 1.83)
Serotype 19A - 1 Month After the Last Dose3.62 (3.30 to 3.97)0.50 (0.41 to 0.60)5.55 (4.86 to 6.34)0.88 (0.71 to 1.10)11.62 (9.75 to 13.86)1.33 (1.04 to 1.70)
Serotype 19F - Before Vaccination0.08 (0.07 to 0.11)0.11 (0.08 to 0.16)0.23 (0.18 to 0.29)0.23 (0.17 to 0.31)0.62 (0.49 to 0.78)0.57 (0.41 to 0.80)
Serotype 19F - 1 Month After the Last Dose4.50 (3.98 to 5.09)0.13 (0.09 to 0.19)5.04 (4.28 to 5.92)0.27 (0.18 to 0.39)5.44 (4.46 to 6.64)0.53 (0.38 to 0.73)
Serotype 23F - Before Vaccination0.11 (0.10 to 0.13)0.11 (0.09 to 0.14)0.19 (0.17 to 0.23)0.22 (0.19 to 0.26)0.54 (0.46 to 0.64)0.45 (0.35 to 0.57)
Serotype 23F - 1 Month After the Last Dose2.04 (1.76 to 2.37)0.17 (0.14 to 0.21)2.26 (1.90 to 2.67)0.27 (0.22 to 0.34)2.80 (2.33 to 3.36)0.44 (0.34 to 0.56)
SecondaryThe Serotype-specific OPA GMT for Each of the Pneumococcal Serotypes in Cohorts 2, 3, 4 Vaccinated With 13 vPnC Compared to Cohorts 2, 3 and 4 Vaccinated With Hib Vaccine.

Serotype-specific OPA titers to the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in a randomly selected subset of approximately 50 participants receiving 13vPnC and approximately 25 participants receiving Hib vaccine from the blood samples taken before vaccination and 1 month after the last 13vPnC vaccination in each of the 3 cohorts.

Time frame:
Cohort 2, 3, 4: Before Vaccination and 1 Month After the Last Dose
Reported as:
Geometric mean · GMT
The Serotype-specific OPA GMT for Each of the Pneumococcal Serotypes in Cohorts 2, 3, 4 Vaccinated With 13 vPnC Compared to Cohorts 2, 3 and 4 Vaccinated With Hib Vaccine.
GMTCohort 2_13vPnCCohort 2_Hib VaccineCohort 3_13vPnCCohort 3_Hib VaccineCohort 4_13vPnCCohort 4_Hib Vaccine
Serotype 1 - Before Vaccination4.1 (3.9 to 4.4)4.2 (3.8 to 4.6)4.0 (4.0 to 4.0)4.2 (3.8 to 4.7)4.6 (4.2 to 5.0)5.5 (4.5 to 6.7)
Serotype 1 - 1 Month After the Last Dose142.7 (103.4 to 196.9)4.9 (3.6 to 6.8)93.3 (70.1 to 124.1)4.8 (3.8 to 6.0)40.9 (31.3 to 53.4)4.4 (3.8 to 5.1)
Serotype 3 - Before Vaccination5.8 (5.0 to 6.7)6.7 (4.5 to 10.0)11.9 (8.6 to 16.5)11.3 (6.9 to 18.5)27.1 (19.2 to 38.4)40.0 (22.7 to 70.7)
Serotype 3 - 1 Month After the Last Dose249.0 (205.7 to 301.5)7.4 (4.9 to 11.3)332.3 (273.3 to 404.1)13.4 (7.7 to 23.4)244.8 (192.0 to 312.1)28.4 (16.2 to 49.7)
Serotype 4 - Before Vaccination5.5 (4.3 to 6.9)5.0 (3.6 to 6.9)6.3 (4.8 to 8.3)9.5 (5.6 to 16.2)23.4 (13.8 to 39.7)15.9 (8.4 to 30.1)
Serotype 4 - 1 Month After the Last Dose2172.2 (1740.7 to 2710.7)10.3 (5.2 to 20.3)2682.8 (2210.4 to 3256.2)10.6 (5.7 to 19.6)4236.3 (3489.6 to 5142.8)19.2 (10.0 to 36.6)
Serotype 5 - Before Vaccination4.3 (3.8 to 4.9)4.0 (4.0 to 4.0)4.2 (3.9 to 4.4)4.1 (3.9 to 4.4)4.7 (4.1 to 5.3)4.2 (3.9 to 4.6)
Serotype 5 - 1 Month After the Last Dose286.3 (214.5 to 382.0)6.2 (4.0 to 9.7)164.5 (131.5 to 205.7)5.1 (3.6 to 7.2)79.3 (57.7 to 109.0)4.8 (4.0 to 5.8)
Serotype 6A - Before Vaccination5.0 (4.1 to 6.3)4.0 (4.0 to 4.0)6.9 (4.9 to 9.8)8.2 (4.7 to 14.3)45.5 (26.5 to 78.0)137.4 (63.3 to 297.9)
Serotype 6A - 1 Month After the Last Dose6042.7 (4830.2 to 7559.6)5.9 (4.0 to 8.8)7661.8 (6116.0 to 9598.4)17.8 (8.1 to 39.1)5849.3 (4364.0 to 7840.2)101.8 (45.7 to 226.8)
Serotype 6B - Before Vaccination5.1 (4.1 to 6.4)4.0 (4.0 to 4.0)8.2 (5.5 to 12.2)9.7 (5.6 to 16.8)53.6 (30.4 to 94.5)94.9 (43.0 to 209.3)
Serotype 6B - 1 Month After the Last Dose2181.6 (1350.1 to 3525.2)5.7 (3.8 to 8.6)4986.3 (3717.6 to 6687.9)20.2 (9.3 to 43.8)3775.2 (2825.1 to 5044.9)117.7 (51.9 to 267.1)
Serotype 7F - Before Vaccination63.0 (35.8 to 111.0)29.6 (12.4 to 70.4)195.8 (114.5 to 334.9)432.7 (213.8 to 875.8)1155.2 (852.6 to 1565.2)892.7 (515.3 to 1546.5)
Serotype 7F - 1 Month After the Last Dose10234.6 (8612.2 to 12162.8)94.0 (37.2 to 237.3)14963.5 (12367.6 to 18104.4)707.1 (361.9 to 1381.6)17107.3 (13842.7 to 21141.8)1090.7 (696.2 to 1708.8)
Serotype 9V - Before Vaccination9.3 (6.3 to 13.8)11.3 (5.9 to 21.5)59.5 (34.1 to 103.7)74.5 (31.0 to 179.0)458.9 (280.9 to 749.8)850.2 (469.4 to 1539.9)
Serotype 9V - 1 Month After the Last Dose4154.1 (3358.6 to 5138.0)20.6 (9.1 to 46.8)7220.1 (5620.9 to 9274.2)154.3 (69.9 to 340.9)10533.5 (7811.9 to 14203.4)795.1 (472.6 to 1337.6)
Serotype 14 - Before Vaccination9.8 (6.5 to 14.7)12.7 (6.2 to 26.3)30.0 (16.1 to 56.1)19.1 (8.5 to 43.0)132.6 (64.8 to 271.5)210.6 (87.7 to 505.5)
Serotype 14 - 1 Month After the Last Dose4108.0 (3342.6 to 5048.8)26.6 (11.4 to 62.3)6885.4 (5642.6 to 8402.0)39.0 (16.3 to 93.2)7504.5 (5718.2 to 9848.9)294.9 (126.5 to 687.1)
Serotype 18C - Before Vaccination4.3 (3.8 to 4.9)4.4 (3.8 to 5.1)6.1 (5.0 to 7.4)6.3 (4.4 to 8.9)12.7 (8.4 to 19.1)20.3 (10.0 to 41.3)
Serotype 18C - 1 Month After the Last Dose1486.6 (1124.6 to 1965.2)6.5 (4.1 to 10.3)1890.4 (1429.0 to 2500.6)7.9 (4.8 to 13.1)2111.9 (1630.6 to 2735.2)24.6 (12.1 to 50.1)
Serotype 19A - Before Vaccination5.3 (4.5 to 6.3)5.8 (4.1 to 8.1)11.1 (7.8 to 15.8)13.8 (7.8 to 24.3)60.3 (37.6 to 96.7)52.0 (24.2 to 111.6)
Serotype 19A - 1 Month After the Last Dose2611.3 (2071.6 to 3291.6)6.4 (4.6 to 8.9)3560.0 (2867.8 to 4419.1)15.5 (8.6 to 28.2)3055.1 (2154.1 to 4333.1)54.3 (27.6 to 107.1)
Serotype 19F - Before Vaccination4.3 (3.9 to 4.8)4.6 (3.7 to 5.7)6.2 (4.9 to 7.8)6.1 (4.5 to 8.3)24.7 (15.7 to 38.9)38.5 (18.1 to 81.8)
Serotype 19F - 1 Month After the Last Dose1158.4 (937.0 to 1432.1)5.9 (4.1 to 8.6)1854.0 (1520.3 to 2260.8)9.5 (5.6 to 16.2)1629.7 (1292.9 to 2054.2)41.1 (19.4 to 86.8)
Serotype 23F - Before Vaccination5.1 (4.1 to 6.3)4.7 (3.4 to 6.4)15.0 (8.8 to 25.6)11.1 (5.6 to 22.0)106.0 (59.5 to 188.9)70.5 (29.5 to 168.3)
Serotype 23F - 1 Month After the Last Dose5640.0 (3950.5 to 8859.4)20.2 (8.5 to 47.7)6693.6 (4464.2 to 10036.4)19.4 (8.8 to 42.8)4234.7 (2916.1 to 6149.5)97.2 (40.8 to 231.2)
SecondaryPercentage of Participants Achieving Pneumococcal Serotype-specific IgG Concentration ≥0.35 mcg/mL for 1 Month After the Last Vaccination in Cohorts 2,3,4 (13vPnC and Hib Vaccine) and 1 Month After the Infant Series in Cohort 1 (13vPnC).

Serotype-specific IgG concentrations to the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in all participants from the blood samples taken 1 month after the infant series in Cohort 1 and the last dose of vaccination (13vPnC or Hib vaccine) in Cohorts 2, 3, 4.

Time frame:
Cohort 1: 1 month after the 3rd dose of 13vPnC. Cohorts 2, 3, 4: 1 month after the last dose of 13vPnC and Hib Vaccine.
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving Pneumococcal Serotype-specific IgG Concentration ≥0.35 mcg/mL for 1 Month After the Last Vaccination in Cohorts 2,3,4 (13vPnC and Hib Vaccine) and 1 Month After the Infant Series in Cohort 1 (13vPnC).
Percentage of ParticipantsCohort 1_Infant SeriesCohort 2_13vPnCCohort 2_Hib VaccineCohort 3_13vPnCCohort 3_Hib VaccineCohort 4_13vPnCCohort 4_Hib Vaccine
Serotype 1100.0 (95.0 to 100.0)99.4 (96.9 to 100.0)4.2 (0.9 to 11.7)97.6 (93.3 to 99.5)10.4 (4.6 to 19.4)99.2 (95.8 to 100.0)23.9 (14.3 to 35.9)
Serotype 383.3 (72.7 to 91.1)97.7 (94.3 to 99.4)4.2 (0.9 to 11.7)94.5 (89.0 to 97.8)11.7 (5.5 to 21.0)98.5 (94.6 to 99.8)19.4 (10.8 to 30.9)
Serotype 4100.0 (95.0 to 100.0)99.4 (96.9 to 100.0)5.6 (1.5 to 13.6)97.6 (93.3 to 99.5)6.5 (2.1 to 14.5)99.2 (95.8 to 100.0)4.5 (0.9 to 12.5)
Serotype 5100.0 (95.0 to 100.0)100.0 (97.9 to 100.0)69.4 (57.5 to 79.8)100.0 (97.1 to 100.0)85.7 (75.9 to 92.6)99.2 (95.8 to 100.0)88.1 (77.8 to 94.7)
Serotype 6A100.0 (95.0 to 100.0)97.7 (94.3 to 99.4)33.3 (22.7 to 45.4)97.6 (93.3 to 99.5)56.6 (44.7 to 67.9)100.0 (97.2 to 100.0)86.6 (76.0 to 93.7)
Serotype 6B100.0 (95.0 to 100.0)96.0 (92.0 to 98.4)23.6 (14.4 to 35.1)97.6 (93.3 to 99.5)50.6 (39.0 to 62.2)99.2 (95.8 to 100.0)77.6 (65.8 to 86.9)
Serotype 7F100.0 (95.0 to 100.0)99.4 (96.9 to 100.0)4.2 (0.9 to 11.9)98.4 (94.4 to 99.8)21.1 (12.5 to 31.9)99.2 (95.8 to 100.0)37.3 (25.8 to 50.0)
Serotype 9V100.0 (95.0 to 100.0)98.3 (95.1 to 99.6)31.9 (21.4 to 44.0)99.2 (95.7 to 100.0)40.8 (29.6 to 52.7)100.0 (97.2 to 100.0)59.7 (47.0 to 71.5)
Serotype 1497.2 (90.3 to 99.7)99.4 (96.9 to 100.0)6.9 (2.3 to 15.5)98.4 (94.4 to 99.8)22.1 (13.4 to 33.0)100.0 (97.2 to 100.0)41.8 (29.8 to 54.5)
Serotype 18C100.0 (95.0 to 100.0)97.7 (94.3 to 99.4)5.6 (1.5 to 13.6)98.4 (94.4 to 99.8)15.6 (8.3 to 25.6)100.0 (97.2 to 100.0)40.9 (29.0 to 53.7)
Serotype 19A100.0 (95.0 to 100.0)100.0 (97.9 to 100.0)63.9 (51.7 to 74.9)100.0 (97.1 to 100.0)90.9 (82.2 to 96.3)100.0 (97.2 to 100.0)94.0 (85.4 to 98.3)
Serotype 19F98.6 (92.5 to 100.0)98.9 (96.0 to 99.9)29.2 (19.0 to 41.1)97.6 (93.3 to 99.5)44.2 (32.8 to 55.9)100.0 (97.2 to 100.0)70.1 (57.7 to 80.7)
Serotype 23F95.8 (88.3 to 99.1)95.5 (91.2 to 98.0)14.1 (7.0 to 24.4)97.6 (93.3 to 99.5)26.0 (16.6 to 37.2)96.9 (92.4 to 99.2)52.2 (39.7 to 64.6)
SecondaryPercentage of Participants Achieving Serotype-specific Pneumococcal OPA Titer ≥ Lower Limit of Quantitation (LLOQ) for 1 Month After the Last Vaccination in Cohorts 2,3,4 (13vPnC and Hib Vaccine) and 1 Month After the Infant Series in Cohort 1 (13vPnC).

Serotype-specific OPA titers to the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in a randomly selected subset of about 50 participants receiving 13vPnC from the blood samples taken 1 month after the infant series in Cohort 1 and the last vaccination (13vPnC or Hib vaccine) in each of the 3 cohorts.

Time frame:
Cohort 1: 1 month after the 3rd dose of 13vPnC. Cohorts 2, 3, 4: 1 month after the last dose of 13vPnC and Hib Vaccine.
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving Serotype-specific Pneumococcal OPA Titer ≥ Lower Limit of Quantitation (LLOQ) for 1 Month After the Last Vaccination in Cohorts 2,3,4 (13vPnC and Hib Vaccine) and 1 Month After the Infant Series in Cohort 1 (13vPnC).
Percentage of ParticipantsCohort 1_Infant SeriesCohort 2_13vPnCCohort 2_Hib VaccineCohort 3_13vPnCCohort 3_Hib VaccineCohort 4_13vPnCCohort 4_Hib Vaccine
Serotype 1100.0 (90.5 to 100.0)96.6 (90.3 to 99.3)5.9 (0.7 to 19.7)96.2 (89.2 to 99.2)7.1 (1.5 to 19.5)95.8 (88.1 to 99.1)5.6 (0.7 to 18.7)
Serotype 3100.0 (90.5 to 100.0)100.0 (95.8 to 100.0)29.4 (15.1 to 47.5)100.0 (95.4 to 100.0)38.1 (23.6 to 54.4)100.0 (94.9 to 100.0)80.6 (64.0 to 91.8)
Serotype 4100.0 (90.5 to 100.0)100.0 (95.8 to 100.0)23.5 (10.7 to 41.2)100.0 (95.4 to 100.0)23.8 (12.1 to 39.5)100.0 (94.9 to 100.0)55.6 (38.1 to 72.1)
Serotype 5100.0 (90.5 to 100.0)100.0 (95.8 to 100.0)14.7 (5.0 to 31.1)100.0 (95.4 to 100.0)4.8 (0.6 to 16.2)98.6 (92.4 to 100.0)11.1 (3.1 to 26.1)
Serotype 6A100.0 (90.5 to 100.0)100.0 (95.8 to 100.0)14.7 (5.0 to 31.1)100.0 (95.4 to 100.0)31.0 (17.6 to 47.1)100.0 (94.9 to 100.0)80.6 (64.0 to 91.8)
Serotype 6B100.0 (90.5 to 100.0)94.3 (87.1 to 98.1)11.8 (3.3 to 27.5)98.7 (93.1 to 100.0)35.7 (21.6 to 52.0)100.0 (94.9 to 100.0)80.6 (64.0 to 91.8)
Serotype 7F100.0 (90.5 to 100.0)100.0 (95.8 to 100.0)61.8 (43.6 to 77.8)100.0 (95.4 to 100.0)90.5 (77.4 to 97.3)100.0 (94.9 to 100.0)100.0 (90.3 to 100.0)
Serotype 9V100.0 (90.5 to 100.0)100.0 (95.8 to 100.0)41.2 (24.6 to 59.3)100.0 (95.4 to 100.0)76.2 (60.5 to 87.9)100.0 (94.9 to 100.0)97.2 (85.5 to 99.9)
Serotype 14100.0 (90.5 to 100.0)100.0 (95.8 to 100.0)41.2 (24.6 to 59.3)100.0 (95.4 to 100.0)45.2 (29.8 to 61.3)100.0 (94.9 to 100.0)83.3 (67.2 to 93.6)
Serotype 18C100.0 (90.5 to 100.0)98.9 (93.8 to 100)14.7 (5.0 to 31.1)98.7 (93.1 to 100.0)21.4 (10.3 to 36.8)100.0 (94.9 to 100.0)52.8 (35.5 to 69.6)
Serotype 19A100.0 (90.5 to 100.0)100.0 (95.8 to 100.0)26.5 (12.9 to 44.4)100.0 (95.4 to 100.0)47.6 (32.0 to 63.6)100.0 (94.9 to 100.0)83.3 (67.2 to 93.6)
Serotype 19F97.3 (85.8 to 99.9)100.0 (95.8 to 100.0)17.6 (6.8 to 34.5)100.0 (95.4 to 100.0)26.2 (13.9 to 42.0)100.0 (94.9 to 100.0)63.9 (46.2 to 79.2)
Serotype 23F97.3 (85.8 to 99.9)95.4 (88.6 to 98.7)35.3 (19.7 to 53.5)96.2 (89.2 to 99.2)33.3 (19.6 to 49.5)97.2 (90.2 to 99.7)72.2 (54.8 to 85.8)
SecondaryNumber of Participants With AE From the Signing of the ICD to 1 Month After the Infant Series in Cohort 1

An AE was any untoward medical occurrence in a study participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage.

Time frame:
From the signing of ICD to 1 month after the 3rd dose of 13vPnC in Cohort 1.
Reported as:
Count of participants · Participants
Number of Participants With AE From the Signing of the ICD to 1 Month After the Infant Series in Cohort 1
ParticipantsCohort 1_Infant Series
Number of Participants With AE From the Signing of the ICD to 1 Month After the Infant Series in Cohort 114
SecondaryNumber of Participants With NDCMCs From 1 Month After Vaccination 3 to Vaccination 4 in Cohort 1

Number of Participants With NDCMCs from 1 month after vaccination 3 to vaccination 4 in Cohort 1. An NDCMC was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects.

Time frame:
From 1 month after Vaccination 3 to Vaccination 4.
Reported as:
Count of participants · Participants
Number of Participants With NDCMCs From 1 Month After Vaccination 3 to Vaccination 4 in Cohort 1
ParticipantsCohort 1_Infant Series
Number of Participants With NDCMCs From 1 Month After Vaccination 3 to Vaccination 4 in Cohort 10
SecondaryNumber of Participants With AE From Toddler Dose Until 1 Month After the Toddler Dose in Cohort 1

Number of Participants With AEs from vaccination 4 to 1 month after vaccination 4 in Cohort 1. An AE was any untoward medical occurrence in a study participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage.

Time frame:
From Vaccination 4 to 1 month after Vaccination 4 in Cohort 1.
Reported as:
Count of participants · Participants
Number of Participants With AE From Toddler Dose Until 1 Month After the Toddler Dose in Cohort 1
ParticipantsCohort 1_ Toddler Dose
Number of Participants With AE From Toddler Dose Until 1 Month After the Toddler Dose in Cohort 15
SecondaryNumber of Participants With NDCMCs From 1 Month to 6 Months After the Toddler Dose in Cohort 1

Number of Participants With NDCMCs from 1 month after vaccination 4 to 6 months after vaccination 4 in Cohort 1. An NDCMC was defined as a disease or medical condition that was not identified prior to study start and was expected to be persistent or otherwise long-lasting in its effects.

Time frame:
From 1 month to 6 months (5 months) after Vaccination 4 in Cohort 1.
Reported as:
Count of participants · Participants
Number of Participants With NDCMCs From 1 Month to 6 Months After the Toddler Dose in Cohort 1
ParticipantsCohort 1 _Toddler Dose
Number of Participants With NDCMCs From 1 Month to 6 Months After the Toddler Dose in Cohort 10
SecondaryNumber of Participants With SAEs From the Signing of the ICD to 6 Months After the Toddler Dose in Cohort 1

Number of Participants With SAEs from the signing of the ICD to 6 months after vaccination 4. An SAE was any untoward medical occurrence at any dose that resulted in death, was life-threatening (immediate risk of death), required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect or considered to be an important medical event.

Time frame:
From the Signing of the ICD to 6 Months After the Vaccination 4.
Reported as:
Count of participants · Participants
Number of Participants With SAEs From the Signing of the ICD to 6 Months After the Toddler Dose in Cohort 1
ParticipantsCohort 1
Number of Participants With SAEs From the Signing of the ICD to 6 Months After the Toddler Dose in Cohort 19
SecondarySerotype-specific IgG GMCs for Each of the Pneumococcal Serotypes in Cohort 1 at 12, 24, 36 and 48 Months After Last Vaccination in Cohort 1 (Infant Series)

Serotype-specific IgG concentrations to the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in all participants from the blood samples taken after last vaccination in Cohort 1. GMC and corresponding 2-sided 95% CI were evaluated. GMs were calculated using all participants with available data for the specified blood draw.

Time frame:
Cohort 1 (infant series): 12, 24, 36 and 48 Months After Last Vaccination in Cohort 1
Reported as:
Geometric mean · Microgram/milliliter
Serotype-specific IgG GMCs for Each of the Pneumococcal Serotypes in Cohort 1 at 12, 24, 36 and 48 Months After Last Vaccination in Cohort 1 (Infant Series)
Microgram/milliliterCohort 1_Infant Series
Serotype 1: 12 Months After Last Vaccination in Cohort 11.35 (1.10 to 1.65)
Serotype 1: 24 Months After Last Vaccination in Cohort 10.88 (0.75 to 1.03)
Serotype 1: 36 Months After Last Vaccination in Cohort 10.77 (0.67 to 0.90)
Serotype 1: 48 Months After Last Vaccination in Cohort 10.79 (0.69 to 0.91)
Serotype 3: 12 Months After Last Vaccination in Cohort 10.27 (0.24 to 0.31)
Serotype 3: 24 Months After Last Vaccination in Cohort 10.22 (0.17 to 0.28)
Serotype 3: 36 Months After Last Vaccination in Cohort 10.18 (0.14 to 0.21)
Serotype 3: 48 Months After Last Vaccination in Cohort 10.19 (0.13 to 0.26)
Serotype 4: 12 Months After Last Vaccination in Cohort 11.10 (0.90 to 1.35)
Serotype 4: 24 Months After Last Vaccination in Cohort 10.54 (0.41 to 0.71)
Serotype 4: 36 Months After Last Vaccination in Cohort 10.58 (0.45 to 0.75)
Serotype 4: 48 Months After Last Vaccination in Cohort 10.32 (0.23 to 0.44)
Serotype 5: 12 Months After Last Vaccination in Cohort 11.56 (1.35 to 1.81)
Serotype 5: 24 Months After Last Vaccination in Cohort 11.03 (0.91 to 1.17)
Serotype 5: 36 Months After Last Vaccination in Cohort 11.03 (0.91 to 1.17)
Serotype 5: 48 Months After Last Vaccination in Cohort 11.19 (1.05 to 1.34)
Serotype 6A: 12 Months After Last Vaccination in Cohort 12.10 (1.71 to 2.59)
Serotype 6A: 24 Months After Last Vaccination in Cohort 11.40 (1.12 to 1.74)
Serotype 6A: 36 Months After Last Vaccination in Cohort 12.79 (2.04 to 3.80)
Serotype 6A: 48 Months After Last Vaccination in Cohort 13.06 (2.30 to 4.06)
Serotype 6B: 12 Months After Last Vaccination in Cohort 12.40 (1.94 to 2.95)
Serotype 6B: 24 Months After Last Vaccination in Cohort 12.12 (1.69 to 2.66)
Serotype 6B: 36 Months After Last Vaccination in Cohort 13.29 (2.57 to 4.21)
Serotype 6B: 48 Months After Last Vaccination in Cohort 13.73 (2.95 to 4.71)
Serotype 7F: 12 Months After Last Vaccination in Cohort 11.55 (1.31 to 1.82)
Serotype 7F: 24 Months After Last Vaccination in Cohort 10.77 (0.67 to 0.88)
Serotype 7F: 36 Months After Last Vaccination in Cohort 10.62 (0.56 to 0.70)
Serotype 7F: 48 Months After Last Vaccination in Cohort 10.53 (0.41 to 0.68)
Serotype 9V: 12 Months After Last Vaccination in Cohort 11.32 (1.11 to 1.57)
Serotype 9V: 24 Months After Last Vaccination in Cohort 10.88 (0.74 to 1.04)
Serotype 9V: 36 Months After Last Vaccination in Cohort 10.84 (0.72 to 0.99)
Serotype 9V: 48 Months After Last Vaccination in Cohort 10.95 (0.78 to 1.16)
Serotype 14: 12 Months After Last Vaccination in Cohort 12.77 (2.30 to 3.34)
Serotype 14: 24 Months After Last Vaccination in Cohort 12.03 (1.52 to 2.70)
Serotype 14: 36 Months After Last Vaccination in Cohort 12.49 (1.76 to 3.51)
Serotype 14: 48 Months After Last Vaccination in Cohort 12.14 (1.34 to 3.42)
Serotype 18C: 12 Months After Last Vaccination in Cohort 11.24 (1.07 to 1.43)
Serotype 18C: 24 Months After Last Vaccination in Cohort 10.72 (0.58 to 0.89)
Serotype 18C: 36 Months After Last Vaccination in Cohort 10.67 (0.54 to 0.81)
Serotype 18C: 48 Months After Last Vaccination in Cohort 10.60 (0.47 to 0.78)
Serotype 19A: 12 Months After Last Vaccination in Cohort 12.92 (2.29 to 3.74)
Serotype 19A: 24 Months After Last Vaccination in Cohort 13.52 (2.68 to 4.63)
Serotype 19A: 36 Months After Last Vaccination in Cohort 16.39 (4.79 to 8.51)
Serotype 19A: 48 Months After Last Vaccination in Cohort 17.53 (6.14 to 9.22)
Serotype 19F: 12 Months After Last Vaccination in Cohort 12.88 (2.32 to 3.57)
Serotype 19F: 24 Months After Last Vaccination in Cohort 12.73 (2.01 to 3.72)
Serotype 19F: 36 Months After Last Vaccination in Cohort 14.06 (2.92 to 5.66)
Serotype 19F: 48 Months After Last Vaccination in Cohort 13.51 (2.56 to 4.80)
Serotype 23F: 12 Months After Last Vaccination in Cohort 12.14 (1.76 to 2.59)
Serotype 23F: 24 Months After Last Vaccination in Cohort 11.72 (1.44 to 2.04)
Serotype 23F: 36 Months After Last Vaccination in Cohort 11.92 (1.58 to 2.34)
Serotype 23F: 48 Months After Last Vaccination in Cohort 12.15 (1.75 to 2.63)

Adverse events

Collected over AE for Cohort 1: from the signing of the ICD to 1 month after Vaccination 3 and from Vaccination 4 to 1 month after Vaccination 4. AE for Cohorts 2,3,4: from the signing of the ICD to 1 month after the last study vaccination. SAE for Cohort 1,2,3,4: From the signing of the ICD to 6 months after the last study vaccination. See below for detailed vaccination timepoints in each cohort.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 10/125 (0%)9/125 (7.2%)13/125 (10.4%)
Cohort 2_13vPnC0/236 (0%)5/236 (2.1%)182/236 (77.1%)
Cohort 2_Hib Vaccine0/117 (0%)1/117 (0.9%)74/117 (63.2%)
Cohort 3_13vPnC0/165 (0%)2/165 (1.2%)99/165 (60%)
Cohort 3_Hib Vaccine0/83 (0%)0/83 (0%)26/83 (31.3%)
Cohort 4_13vPnC0/138 (0%)2/138 (1.4%)66/138 (47.8%)
Cohort 4_Hib Vaccine0/68 (0%)1/68 (1.5%)29/68 (42.6%)
Most frequent serious events
Most frequent serious events
EventCohort 1Cohort 2_13vPnCCohort 2_Hib VaccineCohort 3_13vPnCCohort 3_Hib VaccineCohort 4_13vPnCCohort 4_Hib Vaccine
PneumoniaInfections and infestations7/1251/2360/1171/1650/831/1381/68
LymphadenitisBlood and lymphatic system disorders0/1250/2360/1170/1650/830/1381/68
PyrexiaGeneral disorders0/1253/2360/1170/1650/830/1380/68
Upper respiratory tract infectionInfections and infestations0/1251/2361/1170/1650/830/1380/68
Lower respiratory tract infection bacterialInfections and infestations1/1250/2360/1170/1650/830/1380/68
AsthmaRespiratory, thoracic and mediastinal disorders1/1250/2360/1170/1650/830/1380/68
Otitis mediaInfections and infestations0/1250/2360/1170/1650/831/1380/68
Sleep apnoea syndromeRespiratory, thoracic and mediastinal disorders0/1250/2360/1170/1650/831/1380/68
Febrile convulsionNervous system disorders0/1250/2360/1171/1650/830/1380/68
Toxic encephalopathyNervous system disorders0/1250/2360/1171/1650/830/1380/68
Most frequent other events
Showing 10 of 34
Most frequent other events
EventCohort 1Cohort 2_13vPnCCohort 2_Hib VaccineCohort 3_13vPnCCohort 3_Hib VaccineCohort 4_13vPnCCohort 4_Hib Vaccine
Pyrexia (FEVER)General disorders0/125121/23637/11755/16516/8320/13816/68
Erythema (REDNESS)Skin and subcutaneous tissue disorders1/12568/23627/11742/16510/8336/13815/68
Swelling (SWELLING)General disorders0/12538/2365/11721/1653/8327/13816/68
Tenderness (TENDERNESS)General disorders0/12518/2362/11718/1653/8326/13815/68
PyrexiaGeneral disorders3/12531/23613/1178/1651/834/1380/68
CoughRespiratory, thoracic and mediastinal disorders3/12522/2366/1175/1650/833/1380/68
RhinorrhoeaRespiratory, thoracic and mediastinal disorders0/12522/2369/1171/1650/830/1380/68
Fatigue (FATIGUE)General disorders0/1250/2360/1170/1650/837/1386/68
Decreased appetite (DECREASED APPETITE)Metabolism and nutrition disorders0/1256/2362/11713/1653/830/1380/68
Irritability (IRRITABILITY)Psychiatric disorders0/1253/2361/1177/1652/830/1380/68

Baseline characteristics

Age, Continuous
Age, Continuous(Days)Cohort 1Cohort 2_13vPnCCohort 2_Hib VaccineCohort 3_13vPnCCohort 3_Hib VaccineCohort 4_13vPnCCohort 4_Hib VaccineTotal
Mean49.1 ± 3.78286.0 ± 41.06285.9 ± 40.40————224.0 ± 109.94
Age, Continuous
Age, Continuous(Days)Cohort 1Cohort 2_13vPnCCohort 2_Hib VaccineCohort 3_13vPnCCohort 3_Hib VaccineCohort 4_13vPnCCohort 4_Hib VaccineTotal
Median49.0 (43 to 56)284.0 (216 to 361)281.0 (217 to 360)————260.0 (43 to 361)
Age, Continuous
Age, Continuous(Years)Cohort 1Cohort 2_13vPnCCohort 2_Hib VaccineCohort 3_13vPnCCohort 3_Hib VaccineCohort 4_13vPnCCohort 4_Hib VaccineTotal
Mean———1.5 ± 0.271.6 ± 0.303.3 ± 1.113.3 ± 1.042.3 ± 1.18
Age, Continuous
Age, Continuous(Years)Cohort 1Cohort 2_13vPnCCohort 2_Hib VaccineCohort 3_13vPnCCohort 3_Hib VaccineCohort 4_13vPnCCohort 4_Hib VaccineTotal
Median———1.5 (1 to 2)1.6 (1 to 2)3.1 (2 to 6)3.3 (2 to 6)1.9 (1 to 6)
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1Cohort 2_13vPnCCohort 2_Hib VaccineCohort 3_13vPnCCohort 3_Hib VaccineCohort 4_13vPnCCohort 4_Hib VaccineTotal
Female591155083365637436
Male661216782478231496
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort 1Cohort 2_13vPnCCohort 2_Hib VaccineCohort 3_13vPnCCohort 3_Hib VaccineCohort 4_13vPnCCohort 4_Hib VaccineTotal
Race_Asian1252361171658313868932
Ethnicity_Non-Hispanic/Non-Latino1252361171658313868932
08

Study locations

2 sites
  • Huaiyin District Center for Disease Prevention and Control
    Huaian, Jiangsu 223300, China
  • Guanyun County Disease Control and Prevention
    Lianyungang, Jiangsu, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2018 to primary completion in Aug 2021, 38 months.

Results were first posted in Apr 2024, 2 years 8 months after primary completion.

Of 81 industry-sponsored phase 3 interventional studies under Pneumococcal Infections, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 23. This study's 38 months is above that.

Counting every sponsor, half of 82 studies reached it within 13 months; a quarter within 9 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2018
First posted
Jul 2, 2018
StartActual
Jun 23, 2018
Primary completionActual
Aug 23, 2021
CompletionActual
Oct 13, 2023
Results first posted
Apr 26, 2024
Last update
Nov 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03574389
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jul 2, 2018
Start date
Jun 23, 2018
Primary completion
Aug 23, 2021
Completion
Oct 13, 2023
Results posted
Apr 26, 2024
Last update
Nov 5, 2024

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 13-valent pneumococcal vaccine

Start the discussion